Aspirin Does Not Confer Protection Against Major Ischemic Vascular Events in Patients Diagnosed with Rheumatoid Arthritis

Overview

Journal J Int Med Res

Publisher Sage Publications

Date 2025 Feb 7

PMID 39917854

Authors

Chao Gao

Qiqi Hou

Hongxia Cao

Cangtuo Li

Xu Peng

Quanle Han

Shouling Wu

Kangbo Li

Affiliations

Soon will be listed here.

Abstract

Objective: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by inflammatory arthritis and extra-articular involvement. Patients with RA are at increased risk of developing cardiovascular diseases. This retrospective cohort study aimed to determine whether acetylsalicylic acid (aspirin [ASA]) protects against major ischemic vascular events in patients diagnosed with RA.

Methods: Patients with RA were recruited from a population of 118, 500 participants who were enrolled into the Kailuan Cohort Study between 2014 and 2016. Information regarding demographic characteristics, anthropometric measures, and medical histories were documented. Patients with RA who underwent ASA therapy were propensity score matched at a ratio of 1:4 with patients with RA who did not receive ASA. The risk of ischemic vascular events (myocardial infarction and ischemic stroke) was examined. The relationship between ASA therapy and major ischemic vascular events was analyzed by Cox proportional hazards regression.

Results: A total of 939 patients with RA were included (189 who received ASA and 750 who did not). During the 3.3-year follow-up, six and 35 major ischemic vascular events occurred in the ASA and non-ASA groups, respectively, with no significant between-group difference in the cumulative incidence of such events. Cox proportional hazards regression analysis showed that ASA therapy was not associated with major vascular ischemic events and its subtypes.

Conclusions: ASA did not confer protection against major ischemic vascular events in patients diagnosed with RA.

References

Cofer L, Barrett T, Berger J . Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach. Arterioscler Thromb Vasc Biol. 2022; 42(10):1207-1216. PMC: 9484763. DOI: 10.1161/ATVBAHA.122.318020. View

Daza L, Aguirre M, Jimenez M, Herrera R, Bollain J . Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol. 2006; 26(4):533-7. DOI: 10.1007/s10067-006-0338-7. View

Solomon D, Libby P, Yeomans N, Wang Q, Wolski K, Nissen S . The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial. Rheumatology (Oxford). 2018; 57(8):1364-1369. DOI: 10.1093/rheumatology/key105. View

Ruscitti P, Cipriani P, Liakouli V, Iacono D, Pantano I, Margiotta D . Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Arthritis Res Ther. 2019; 21(1):204. PMC: 6724256. DOI: 10.1186/s13075-019-1975-y. View

Weisman S, Graham D . Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002; 162(19):2197-202. DOI: 10.1001/archinte.162.19.2197. View

Meissner Y, Richter A, Manger B, Tony H, Wilden E, Listing J . Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis. 2017; 76(9):1583-1590. PMC: 5561376. DOI: 10.1136/annrheumdis-2017-211209. View

Lee D, Sheen S, Lee D, Jang J, Lee D, Shin S . Association between ischemic stroke and seropositive rheumatoid arthritis in Korea: A nationwide longitudinal cohort study. PLoS One. 2021; 16(5):e0251851. PMC: 8128246. DOI: 10.1371/journal.pone.0251851. View

Wiseman S, Ralston S, Wardlaw J . Cerebrovascular Disease in Rheumatic Diseases: A Systematic Review and Meta-Analysis. Stroke. 2016; 47(4):943-50. DOI: 10.1161/STROKEAHA.115.012052. View

Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger P . Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011; 342:c7086. PMC: 3019238. DOI: 10.1136/bmj.c7086. View

10.

Davignon J, Ganz P . Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109(23 Suppl 1):III27-32. DOI: 10.1161/01.CIR.0000131515.03336.f8. View

11.

McNeil J, Wolfe R, Woods R, Tonkin A, Donnan G, Nelson M . Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018; 379(16):1509-1518. PMC: 6289056. DOI: 10.1056/NEJMoa1805819. View

12.

Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

13.

Shibata K, Akagi Y, Nozawa N, Shimomura H, Aoyama T . Influence of nonsteroidal anti-inflammatory drugs on aspirin's antiplatelet effects and suggestion of the most suitable time for administration of both agents without resulting in interaction. J Pharm Health Care Sci. 2017; 3:9. PMC: 5345232. DOI: 10.1186/s40780-017-0078-7. View

14.

Stuntz M, Bernstein B . Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015. Prev Med Rep. 2017; 5:183-186. PMC: 5219640. DOI: 10.1016/j.pmedr.2016.12.023. View

15.

Fuster V, Sweeny J . Aspirin: a historical and contemporary therapeutic overview. Circulation. 2011; 123(7):768-78. DOI: 10.1161/CIRCULATIONAHA.110.963843. View

16.

Davidson K, Barry M, Mangione C, Cabana M, Chelmow D, Coker T . Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022; 327(16):1577-1584. DOI: 10.1001/jama.2022.4983. View

17.

Avina-Zubieta J, Abrahamowicz M, De Vera M, Choi H, Sayre E, Rahman M . Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford). 2012; 52(1):68-75. DOI: 10.1093/rheumatology/kes353. View

18.

Linos A, WORTHINGTON J, OFallon W, Kurland L . The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol. 1980; 111(1):87-98. DOI: 10.1093/oxfordjournals.aje.a112878. View

19.

Solomon D, Karlson E, Rimm E, Cannuscio C, Mandl L, Manson J . Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003; 107(9):1303-7. DOI: 10.1161/01.cir.0000054612.26458.b2. View

20.

van Halm V, Peters M, Voskuyl A, Boers M, Lems W, Visser M . Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis. 2008; 68(9):1395-400. DOI: 10.1136/ard.2008.094151. View